
Both Australia and Canada are known for having universal healthcare systems that aim to make healthcare accessible and affordable for their citizens. However, one area that continues to draw attention is the cost of prescription drugs. While neither country offers completely free medications for everyone, both governments take steps to regulate drug prices and ensure affordability. Still, their approaches differ in terms of structure, coverage, and effectiveness. This article compares how Australia and Canada handle prescription drug pricing and what that means for patients.
1. Government Regulation and Pricing Controls
Australia: Centralized Price Negotiation via PBS
Australia’s drug pricing is managed by the Pharmaceutical Benefits Scheme (PBS), a government-run program that lists approved medications eligible for subsidies. The PBS uses a rigorous process to negotiate prices directly with pharmaceutical companies. The Pharmaceutical Benefits Advisory Committee (PBAC) evaluates new drugs based on clinical effectiveness and cost-efficiency before deciding whether they should be included on the PBS list.
The result? Medication prices are significantly lower than in many other countries. Once a drug is on the PBS, the government pays most of the cost, and patients pay only a small co-payment, which is capped and regulated.
As of 2025, general patients pay AUD $31.60 or less per prescription, while concession cardholders pay even less—around AUD $7.70.
Canada: A Patchwork of Provincial and Private Systems
Canada does not have a single national drug plan like Australia’s PBS. Instead, it operates a patchwork of provincial public drug plans, combined with private insurance and out-of-pocket payments. The Patented Medicine Prices Review Board (PMPRB) regulates the maximum price of patented drugs sold in Canada to prevent excessive costs, but the government does not centrally negotiate prices in the same way Australia does.
While provincial plans may offer coverage for specific groups (seniors, low-income individuals, etc.), the majority of working Canadians rely on private drug insurance through employers or pay out of pocket.
2. Patient Costs and Access
Australia: Predictable and Affordable Costs
Australians benefit from predictable costs when filling prescriptions. Since the PBS sets co-payment caps, most people know exactly how much they will pay, and no one is charged more than the set limit—even for expensive medications. There’s also a Safety Net scheme that reduces or eliminates costs once an individual or family spends a certain amount annually on PBS medicines.
Canada: Uneven Costs and Coverage Gaps
In Canada, patient costs for prescription drugs vary significantly depending on province, insurance coverage, and income level. Many Canadians without employer coverage or not eligible for provincial plans face high out-of-pocket expenses. Some may even skip filling prescriptions due to cost concerns—something that is rare in Australia due to the PBS protections.
3. Calls for Reform in Canada
Canada has been debating the implementation of a national pharmacare program that would function similarly to Australia’s PBS. Advocates argue that this would lower costs, improve access, and reduce inequalities. However, progress has been slow due to political and financial challenges.
Conclusion
Australia and Canada share a commitment to affordable healthcare, but their approaches to prescription drug pricing diverge. Australia’s centralized PBS system allows for negotiated prices, predictable patient costs, and widespread access. Canada’s fragmented approach creates variation in pricing and coverage, with many Canadians relying on private insurance to bridge the gap. As both countries continue to refine their systems, Australia’s model offers a strong example of how government intervention can effectively manage drug prices while ensuring accessibility for all.